Canada Next-Generation Sequencing (NGS) Services Market (2017-2022)
The Canada Next-Generation Sequencing (NGS) Services Market was valued at $18.57 Million in 2017 and projected to reach to $22.5 Million by 2022, representing a compound annual growth rate of 3.9%. Canada's NGS services market is positioned for steady growth as healthcare institutions and research organizations continue adopting advanced genomic sequencing technologies.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Canada Next-Generation Sequencing (NGS) Services Market Trends and Insights
- Canada's NGS services sector reflects steady adoption of genomic sequencing technologies across research institutions, clinical diagnostics, and pharmaceutical development.
- The market in Canada is characterized by increasing investment in precision medicine and genomic research infrastructure, supported by government funding and academic partnerships. The growth trajectory in Canada demonstrates moderate but consistent expansion compared to global market dynamics.
- Canada's NGS services market benefits from a robust healthcare system, strong research capabilities, and growing demand for personalized medicine applications.
- Between 2017 and 2022, Canada is expected to see incremental market penetration as healthcare providers and research organizations expand their genomic sequencing capabilities.
- The Canadian market reflects regional healthcare priorities and regulatory frameworks that support innovation in genomic diagnostics and research services..
Key Market Statistics
- CAGR (2017-2022) 3.9% CAGR
- Market Size, 2017 ~USD 18.57 Million
- Forecast, 2022 ~USD 22.5 Million
- Country Canada
Canada Next-Generation Sequencing (NGS) Services Market Overview
Market Valuation Growth :
Canada's NGS services market grew from $18.57 million in 2017 to $22.5 million by 2022, demonstrating consistent expansion in genomic sequencing adoption across the country.
Steady CAGR Performance :
With a 3.9% CAGR through 2022, Canada's NGS market shows moderate but reliable growth, significantly lower than the global 21% CAGR, indicating a maturing regional market.
Multi-Sector Adoption :
Canadian NGS services are increasingly utilized across research institutions, clinical diagnostics laboratories, and pharmaceutical development companies, reflecting diversified market penetration.
Clinical and Research Integration :
Canada's healthcare system integration of NGS technologies in both academic research and clinical settings positions the country as a stable market for genomic sequencing services.
Canada Next-Generation Sequencing (NGS) Services Market Dynamics
- The 3.9% CAGR reflects a mature market with established infrastructure and regulatory frameworks supporting genomic medicine implementation.
- Canadian research institutions and clinical laboratories are increasingly integrating NGS into diagnostic workflows and precision medicine initiatives. Future growth will be driven by expanding clinical applications, increased funding for genomic research, and growing demand for personalized medicine approaches.
- While Canada's growth rate trails the global average, the market benefits from strong healthcare infrastructure, government support for life sciences research, and increasing collaboration between academic and commercial genomic service providers..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Danaher Corporation
Key Takeaways
- Canada's NGS Services Market valued at $18.57 million in 2017, growing to $22.5 million by 2022 at 3.9% CAGR
- Canada demonstrates steady adoption of genomic sequencing across clinical diagnostics, research, and pharmaceutical applications
- Canada's market growth is driven by precision medicine initiatives and government-supported genomic research infrastructure
- Canada's NGS services sector benefits from strong academic institutions and healthcare system integration supporting genomic innovation
Next-Generation Sequencing (NGS) Services Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2017 |
| Fastest Growing Segment | AGRICULTURE & ANIMAL RESEARCH (Application) |
| Forecast Period | 2017–2022 |
| Growth Rate | CAGR of 21% from 2017 to 2022 |
| Largest Segment | DIAGNOSTICS (Application) |
| Market Size Base Year (Billions) | ~USD 1.06 (2017) |
| Revenue Forecast (Billions) | ~USD 2.748 (2022) |
| Segments Covered | Type, Application, End User, Technology |
Canada Next-Generation Sequencing (NGS) Services Market Report Segmentation
4 segment dimensions are covered across the global market.
By Type
- Chip-Seq
- De Novo Sequencing
- Exome Sequencing
- Methyl-Seq
- Other Ngs Services
- Other Services
- Rna-Seq
- Targeted Sequencing/Custom Gene Panels
- Targeted Sequencing/Gene Panels
- Whole-Genome Sequencing
By Application
- Agriculture & Animal Research
- Biomarker Discovery
- Diagnostics
- Drug Discovery
- Infectious Diseases
- Oncology
- Other Applications
- Other Applications*
- Other Diagnostic Applications
- Rare Genetic Disorders
- Reproductive Health
By End User
- Academic & Government
- Academic & Government Institutes And Research Centers
- Hospitals & Clinics
- Other End Users
- Other End Users*
- Pharmaceutical & Biotechnology Companies
By Technology
- Ion Semiconductor Sequencing
- Nanopore Sequencing
- Sequencing By Synthesis
- Single-Molecule Real-Time Sequencing
Target Audience
- NGS Service Providers : Companies offering sequencing services need Canada-specific market data to assess market size, growth potential, and competitive opportunities within the $22.5M projected market.
- Diagnostic Laboratory Operators : Clinical and research laboratories in Canada require market intelligence to understand adoption trends, pricing dynamics, and demand forecasts for NGS-based diagnostic services.
- Pharmaceutical & Biotech Companies : Canadian and international pharma firms need regional market insights to evaluate NGS service demand for drug development, clinical trials, and precision medicine initiatives.
- Healthcare Investment Firms : Investors and venture capital firms focused on Canadian life sciences require market data to identify investment opportunities and assess growth potential in the genomic sequencing sector.
- Government & Research Institutions : Canadian research organizations and health authorities need market analysis to inform funding decisions, policy development, and strategic planning for genomic medicine infrastructure.
Key Companies in the Canada Next-Generation Sequencing (NGS) Services Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ILLUMINA, INC. | United States | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| PERKINELMER, INC. | United States | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| EUROFINS SCIENTIFIC SE | Luxembourg | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| MACROGEN, INC. | South Korea | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| QIAGEN N.V. | Netherlands | Public Company | Targeted sequencing services (panels, amplicon, gene panels),RNA-Seq services,Exome and de novo sequencing services, |
| DNA LINK, INC. | South Korea | Public Company | Whole genome & De Novo sequencing services,Whole exome & targeted sequencing services,Transcriptome & single-cell RNA sequencing, |
| TAKARA BIO INC. (PART OF TAKARA HOLDING COMPANY INC.) | Japan | ||
| NOVOGENE CORPORATION | China | Public Company | Whole genome and targeted sequencing services (incl. human/animal/plant/microbial WGS and targeted panels),Transcriptomics and single-cell sequencing (mRNA, lncRNA, small RNA, single-cell, spatial),De novo, metagenomics, and microbiome sequencing, |
| PERSONALIS, INC. | United States | Public Company | Oncology MRD and monitoring (NeXT Personal, NeXT Personal Dx),Comprehensive tumor profiling (ImmunoID NeXT, NeXT Dx),Population and research sequencing (WES/WGS services), |
ILLUMINA, INC.
Illumina, Inc. is a public company founded in 1998 and headquartered in the United States with 8,625 employees. The company is a leader in DNA sequencing and genetic analysis technologies.
PERKINELMER, INC.
PerkinElmer, Inc. is a public company founded in 1937 and based in the United States with 11,000 employees. The company provides diagnostic and research solutions across life sciences and environmental testing.
EUROFINS SCIENTIFIC SE
Eurofins Scientific SE is a public company founded in 1987 and headquartered in Luxembourg with 65,694 employees. The company operates a network of laboratories providing testing and analytical services across multiple industries.
MACROGEN, INC.
Macrogen, Inc. is a public company founded in 2000 and based in South Korea with 293 employees. The company provides genomic research services including DNA sequencing and analysis.
QIAGEN N.V.
QIAGEN N.V. is a public company founded in 1984 and headquartered in the Netherlands with 5,500 employees. The company develops and manufactures molecular diagnostics and life sciences tools.
DNA LINK, INC.
DNA Link, Inc. is a public company founded in 2000 and based in South Korea with 84 employees. The company offers genomic analysis and genetic testing services.
TAKARA BIO INC. (PART OF TAKARA HOLDING COMPANY INC.)
Takara Bio Inc. is a company based in Japan and operates as part of Takara Holding Company Inc. The company specializes in biotechnology and life sciences research products.
NOVOGENE CORPORATION
Novogene Corporation is a public company founded in 2011 and based in China with 2,225 employees. The company provides genomic sequencing and bioinformatics analysis services.
PERSONALIS, INC.
Personalis, Inc. is a public company founded in 2011 and based in the United States with 260 employees. The company develops genomic testing and analysis solutions for precision medicine.
Reasons to Buy this Report
- Canada-Specific Market Sizing : Obtain precise valuation data for Canada's NGS services market with historical baseline (2017: $18.57M) and forecast projections (2022: $22.5M) to support regional business planning.
- Competitive Landscape Intelligence : Understand Canada's unique market dynamics, growth trajectory at 3.9% CAGR, and regional adoption patterns to identify competitive positioning opportunities within the Canadian healthcare ecosystem.
- Sector-Specific Insights : Access detailed analysis of NGS adoption across Canadian research institutions, clinical diagnostics, and pharmaceutical development to target high-potential customer segments.
- Strategic Investment Decisions : Make informed decisions about market entry, expansion, or partnership strategies in Canada by leveraging comprehensive market data and growth forecasts specific to the region.
- Regulatory and Infrastructure Context : Gain insights into Canada's healthcare regulatory environment and institutional readiness for NGS adoption to align product development and go-to-market strategies accordingly.
Frequently asked questions
What is the market size of NGS services in Canada?
Canada's NGS Services Market was valued at $18.57 million in 2017 and is forecast to reach $22.5 million by 2022.
What is the growth rate of Canada's NGS services market?
Canada's NGS services market is expected to grow at a CAGR of 3.9% between 2017 and 2022.
What are the primary drivers of NGS services growth in Canada?
Canada's NGS market growth is driven by increasing adoption of precision medicine, government funding for genomic research, and expansion of clinical diagnostic applications.
Which sectors are adopting NGS services in Canada?
Canada's NGS services are being adopted across clinical diagnostics, pharmaceutical research and development, academic research institutions, and personalized medicine applications.
How does Canada's NGS market compare to global trends?
Canada's NGS market growth rate of 3.9% is more moderate than the global CAGR of 21%, reflecting regional market maturity and healthcare system characteristics.
RESEARCH METHODOLOGY
Get the Full Next-Generation Sequencing (NGS) Services Market Report
Full forecast, segment splits, and company analysis for all Next-Generation Sequencing (NGS) Services Market.
- Germany Next-Generation Sequencing (NGS) Services Market
- France Next-Generation Sequencing (NGS) Services Market
- China Next-Generation Sequencing (NGS) Services Market
- Japan Next-Generation Sequencing (NGS) Services Market
- India Next-Generation Sequencing (NGS) Services Market
- U.S. Next-Generation Sequencing (NGS) Services Market
- Roe Next-Generation Sequencing (NGS) Services Market
- U.K. Next-Generation Sequencing (NGS) Services Market
- Roapac Next-Generation Sequencing (NGS) Services Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
